Veterinary Medicines

PROGRAM Plus

Authorised
  • Milbemycin oxime
  • Lufenuron
Download as PDF

Product identification

Medicine name:
PROGRAM Plus
***created in error - dummy forseen for nullification***
Active substance:
  • Milbemycin oxime
  • Lufenuron
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    2.30
    milligram(s)
    /
    1.00
    Tablet
  • Lufenuron
    46.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:
  • Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton
  • Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Elanco France S.A.S.
Responsible authority:
  • Federal Office Of Consumer Protection And Food Safety
Authorisation number:
  • ***created in error***
Date of authorisation status change:
Reference member state:
  • Italy
Procedure number:
  • IT/V/0106/001
Concerned member states:
  • Austria
  • Germany
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."